Form 4: Kyverna CTO Exercises Options, Sells Shares

Kyverna Therapeutics' Chief Technology Officer, Karen Marie Walker, exercised stock options and subsequently sold common stock under a pre-arranged 10b5-1 plan.

Summary

• Karen Marie Walker, Chief Technology Officer of Kyverna Therapeutics, Inc. (KYTX), executed transactions on December 15, 2025.
• Ms. Walker acquired 23,998 shares of common stock by exercising stock options at a price of $4.83 per share.
• Immediately following the option exercise, she disposed of 23,998 shares of common stock at a sale price of $12.20 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 plan, which was adopted by Ms. Walker on September 12, 2025.
• After these reported transactions, Ms. Walker beneficially owns 22,636 shares of common stock and 85,865 stock options.
• The stock options have an exercise price of $4.83 and an expiration date of November 5, 2033, with vesting terms including 25% on January 1, 2025, and 1/48th monthly thereafter, subject to continuous service.

Sentiment

Score: 6

Explanation: The transaction is a routine insider sale under a pre-arranged plan, indicating personal financial planning rather than a negative view of the company. The sale at a higher price than exercise is positive for the insider.

Positives

• The Chief Technology Officer realized a significant profit by selling shares at $12.20 after exercising options at $4.83, indicating a positive financial outcome for the insider.

Negatives

• Insider selling, even under a pre-arranged 10b5-1 plan, can sometimes be perceived negatively by some market participants, although it is often for personal financial planning.

Future Outlook

This Form 4 filing reports a past insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing details a routine insider transaction for personal financial planning by a company executive. It does not provide information directly related to broader industry trends or competitive landscape, but rather reflects an individual's management of their equity compensation.

Stakeholder Impact

• Shareholders may note the insider sale, but given it was executed under a Rule 10b5-1 plan, it is generally interpreted as a pre-scheduled personal financial event rather than a signal of management's view on the company's immediate prospects.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction where the Chief Technology Officer exercised options and sold shares under a pre-arranged 10b5-1 plan. Such transactions are typically for personal financial management and do not inherently signal a change in the company's fundamental outlook. The sale price being significantly above the exercise price indicates a profitable event for the insider. Without additional information on company performance or strategic shifts, this filing alone does not warrant a change from a 'hold' position.

Keywords

Kyverna Therapeutics, KYTX, Form 4, Insider Transaction, Stock Options, Common Stock, Rule 10b5-1, Karen Marie Walker, Chief Technology Officer